Thalidomide for previously untreated indolent or smoldering multiple myeloma.
about
Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM): novel biological insights and development of early treatment strategiesSeven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic diseaseSerum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significanceDoes my patient with a serum monoclonal spike have multiple myeloma?Smoldering multiple myeloma requiring treatment: time for a new definition?Poor tolerance to high doses of thalidomide in patients with primary systemic amyloidosis.Peripheral neuropathy and new treatments for multiple myeloma: background and practical recommendations.Impact of optimal follow-up of monoclonal gammopathy of undetermined significance on early diagnosis and prevention of myeloma-related complications.Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma: a review of the current understanding of epidemiology, biology, risk stratification, and management of myeloma precursor disease.Management of thalidomide toxicity.Long-term results of single-agent thalidomide as initial therapy for asymptomatic (smoldering or indolent) myelomaHow I treat smoldering multiple myeloma.Dilemmas in treating smoldering multiple myeloma.Thalidomide for erythema nodosum leprosum and other applications.Monoclonal gammopathies of undetermined significance: a review.Bone marrow angiogenesis and progression in multiple myeloma: clinical significance and therapeutic approach.Effect of thalidomide on stem cell collection and engraftment in patients with multiple myeloma.Thalidomide and its derivatives: new promise for multiple myeloma.Thalidomide for the treatment of multiple myeloma.Targeted therapy in multiple myeloma.Therapeutic renaissance of thalidomide in the treatment of haematological malignancies.Angiogenesis and hematological malignancies.CD4+CD25+ cells in multiple myeloma related renal impairment.Low-dose thalidomide-induced agranulocytosis in a multiple myeloma patient treated at diagnosis.Angiogenic inhibitors: a new therapeutic strategy in oncology.Investigational treatments for multiple myeloma.Review of thalidomide in the treatment of newly diagnosed multiple myeloma.54-year-old woman with fatigue, back pain, and hypercalcemiaSmoldering multiple myeloma: present position and potential promises.Is it time for preemptive drug treatment of asymptomatic (smoldering) multiple myeloma?The road to cure in multiple myeloma starts with smoldering disease.Biological evaluation of both enantiomers of fluoro-thalidomide using human myeloma cell line H929 and others.Novel therapies delay the progression of smoldering multiple myeloma: Case report and discussion.Thalidomide effects in the post-transplantation setting in patients with multiple myeloma.Modifications of the mouse bone marrow microenvironment favor angiogenesis and correlate with disease progression from asymptomatic to symptomatic multiple myeloma.Genomic analysis of high-risk smoldering multiple myeloma.The adverse effects of thalidomide in relapsed and refractory patients of multiple myeloma.Thalidomide as initial therapy for early-stage myeloma.Thalidomide therapy induces response in relapsed mantle cell lymphoma.Efficacy of thalidomide in a child with histiocytic sarcoma following allogeneic bone marrow transplantation for T-ALL.
P2860
Q24607241-3AE7CE73-80CE-42B3-92FF-F9459AF4BE39Q24651269-1F69A9E8-D578-4C0E-8844-7928E3F6C94FQ24669898-8BF7D05D-6F15-493A-ACF1-10E35977F1E3Q26821981-1C675ADA-3D4A-4952-A942-63549053F47EQ26996579-41D6CE41-3CA7-4A7B-9D6B-64D773C95AECQ33151135-54DA98CF-8CFB-4A6B-AC56-6C138459116CQ33632270-9898D2A6-5DE3-45E8-9A7E-43B1C832F4F8Q34184698-97365136-1B82-4AA4-908E-1289929907F2Q34316559-FD49A3C2-5380-4E0B-9913-0995342CBBEFQ34343991-D67ABF61-A778-44A2-A1BA-B55B0B46BCE9Q34497797-E9154775-0BDA-4D3A-87B0-0CE4FCB6F46CQ34580094-1DADC3A0-EAC0-4FA5-A04D-9E21940A1519Q34716500-AD6B8404-8933-41FC-B8D5-7B01969E7402Q35101473-F52032C7-9B5F-43C6-9682-DF11F6B69BCAQ35170927-200D49E7-8304-4980-B373-9A939CD25C56Q35175287-E8AD5FDD-E995-4875-8B64-B5283B30BC34Q35210732-FEA8A202-6D1E-439A-AC97-9DB9FC3BE110Q35569462-F711FEDF-78D5-4A64-AD69-EE3EA1FFA930Q35870500-91797D95-C2CC-4CD2-ACAF-B5A44258A89BQ36108614-0B467297-DFA6-4662-AF41-C3B3F33C8793Q36171864-88EA58D6-33D0-4C91-9C84-E977E1F0EA7CQ36194525-9764F21B-82B2-4D32-BC7A-40EAB99C07BEQ36275650-6E4886BE-B9B4-4AB8-9E8F-45B1CA7EEB3CQ36303471-A77A75DF-748A-43B4-B8A2-1D32925EEACAQ36306264-C1FDB7F1-CD3B-457E-A70D-93947EC6B4CBQ36654336-133223B7-A687-47E1-BB88-C86AA0F2F7EBQ37160347-454C63F5-884D-435B-83CF-954FDB58DA51Q37454464-461BDB5D-994C-422E-91A3-0155E6F01BA9Q38151230-0CC8FC9F-1CE1-430F-9F0B-5CF853B14B7DQ38190593-CA59CC69-99F1-47EA-BDCF-81313AAA365CQ38494968-44CB8BCC-3FBE-4D65-B26B-93D666C1E585Q38649220-D9627568-1808-4A07-B9E7-01F1BF93080AQ39689809-1118A02B-A1F7-4DC8-809C-90E8C808378DQ40531242-BA787C02-664E-4C81-8B22-C99C05AA9281Q41591687-C856B6AB-6F89-434C-9D1C-DABE3EF89B94Q41847877-9E4BD5B2-9C8C-438F-9032-F7E1B642D0B9Q44177889-F42A84AD-CB00-4A2A-9025-53328B146866Q44394897-2A9C1134-DD4F-4F77-B355-7EBB57AFE3EDQ44582819-B279DA4F-4B30-4C62-8672-F8CC9B7D231EQ44598673-F149AFC5-6B58-47F3-97DB-1233E5CCBEA5
P2860
Thalidomide for previously untreated indolent or smoldering multiple myeloma.
description
2001 nî lūn-bûn
@nan
2001 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Thalidomide for previously untreated indolent or smoldering multiple myeloma.
@ast
Thalidomide for previously untreated indolent or smoldering multiple myeloma.
@en
type
label
Thalidomide for previously untreated indolent or smoldering multiple myeloma.
@ast
Thalidomide for previously untreated indolent or smoldering multiple myeloma.
@en
prefLabel
Thalidomide for previously untreated indolent or smoldering multiple myeloma.
@ast
Thalidomide for previously untreated indolent or smoldering multiple myeloma.
@en
P2093
P356
P1433
P1476
Thalidomide for previously untreated indolent or smoldering multiple myeloma.
@en
P2093
Dispenzieri A
Rajkumar SV
P2888
P304
P356
10.1038/SJ.LEU.2402183
P577
2001-08-01T00:00:00Z
P5875
P6179
1026754679